Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates
Location: United States, Massachusetts, Lexington
Employees: 51-200
Total raised: $127M
Founded date: 2006
Investors 3
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.11.2021 | - | $65M | - |
| 17.05.2021 | - | $32M | - |
| 12.06.2017 | - | $30M | Hercules C... |
Mentions in press and media 18
| Date | Title | Description |
| 15.03.2025 | Indian Pharma's Bold Leap into the U.S. Market: A New Era of Acquisitions | The Indian pharmaceutical industry is on the move. Like a ship navigating through stormy seas, companies are expanding their reach into the U.S. market. This surge in acquisitions is not just a trend; it’s a strategic response to shifting t... |
| 10.03.2025 | Sun Pharma to acquire Checkpoint Therapeutics Inc, for a consideration of up to $355 million | Mumbai-based Sun Pharmaceutical Industries has entered into an agreement with Checkpoint Therapeutics Inc, to acquire the immunotherapy and targeted-oncology company for a consideration of up to $355 million ( ₹3,088 crore). This is Sun Pha... |
| 19.01.2023 | Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata | Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients... |
| 08.11.2021 | Concert Pharmaceuticals Announces $65 Million Financing Financing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management - Form 8-K | Concert Pharmaceuticals Announces $65 Million Financing Financing Provided by Leading Healthcare Funds BVF Partners L.P. and RA Capital Management Lexington, MA (November 4, 2021) - Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announc... |
| 04.11.2021 | Concert Pharmaceuticals Announces $65 Million Financing | Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into an agreement with BVF Partners L.P. (BVF) and RA Capital Management (RA) to raise gross proceeds of $65 million. In addition, Concert will have the potent... |
| 17.05.2021 | CONCERT PHARMACEUTICALS, INC. Concert Pharmaceuticals : Announces Sale of VX-561 Milestones to Vertex for $32 Million | Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has purchased the potential future milestones under the companies’ 2017 asset purchase agreement relating to VX-561 (deutiv... |
| 13.11.2018 | Concert’s initial alopecia data fall short against Pfizer, prompting investor blow back | An interim analysis of mid-stage data on Concert Pharmaceuticals’ $CNCE JAK inhibitor for alopecia may have thinned its potential against Pfizer’s $PFE rival drugs in development. On Monday, Concert reported the 8 mg d... |
| 27.04.2018 | Vertex's rapid-fire PhIII program hits a roadblock at the FDA. Will regulators force rival Galapagos to slow down too? | Vertex’s R&D team doesn’t make many mistakes. So during yesterday’s Q1 call, a group of analysts were quick to pick up on a rare stumble that just might make it more vulnerable to a rival like Galapagos. Geoffrey Porges,... |
| 22.12.2017 | Synergy CEO passes torch to CCO Troy Hamilton; President Steven Kafka resigns from Foundation; AbbVie vet John Leonard to helm Intellia | Troy Hamilton → Marking a new phase for the biotech, Synergy Pharmaceuticals $SYGP announced that co-founder and Trulance co-inventor Gary Jacob is passing the CEO baton to Troy Hamilton. Joining Synergy in 2015, Hamilto... |
| 12.06.2017 | Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital | LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.0 million venture debt financing agreement with Hercules Capital, Inc. “This non-dilutive financing further exten... |
Show more